SYRACUSE, N.Y. — DUB Therapeutics, an Upstate Medical University–based startup company, won the $10,000 Alan W. Rothschild Innovation Award at the Biotech Innovation Pitch competition held Oct. 27 at the CNY Biotech Accelerator in Syracuse.
DUB Therapeutics works at creating a siRNA therapeutic that aims to prevent corneal scarring and inflammation and promote regenerative healing, per the Upstate Medical announcement.
The Alan W. Rothschild Innovation Award honors Rothschild’s life, which was “one of creativity and entrepreneurial spirit” and provides support to individuals and startups who demonstrate excellence in innovation, Upstate said. Its purpose is to further the development and advancement of emerging science and new technologies.
(Sponsored)
Inflation and Insurance Rates: How to Offset the Impact
Many industries have been hit by inflation where it hurts the most, our pockets. Inflation is raising the price of goods and services including food, housing, transportation, and medical care.
What Distressed Property Owners Might Expect From the IRS
The commercial real estate market has been rough for some time, and the residential market has seen wild fluctuations. Inflation, high interest rates and decreased demand for office space have
DUB Therapeutic co-founders — CSO Audrey Bernstein, PhD, and CEO Tere Williams — are hoping to change how corneal injuries and scarring that can lead to vision loss are treated.
A panel of five judges selected DUB Therapeutics after listening to brief pitches from the five competitors at the Biotech Innovation Pitch competition.
The additional finalists at the Biotech Innovation Pitch event were all awarded $2,500 each. They included Pretip; BiRed Imaging; Azimuth Biologics; and Triton Bio. The finalists are all clients of the CNY Biotech Accelerator.
The Rothschild Award is one of several honors DUB Therapeutics has collected in recent years, Upstate said. In 2023, the company was awarded the $50,000 top prize at the SUNY Start Up Summer School (S4) Demo Day. Two months later, it won a $50,000 grant at FuzeHub’s commercialization competition.
Judges for the competition included Ann and David Rothschild, sponsors of Alan W. Rothschild Innovation Award; Vicki Quigley; Eileen Pezzi, Upstate VP for development and executive director of the Upstate Foundation; Winthrop Thurlow, executive director of LifeSciencesNY and Michael Hausladen, general manager of LOTTE Biologics in Syracuse.
